Hansoh Pharmaceutical Group Company Limited
HNSPF
$5.20
$0.4910.40%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.29% | 4.12% | 39.54% | 37.43% | 11.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.29% | 4.12% | 39.54% | 37.43% | 11.24% |
| Cost of Revenue | 6.26% | 7.10% | 6.75% | 5.13% | 4.69% |
| Gross Profit | 3.00% | 3.82% | 43.92% | 41.74% | 11.93% |
| SG&A Expenses | 8.99% | 9.86% | 0.39% | -1.13% | 1.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -152.16% | -152.58% | 215.06% | 210.29% | 233.95% |
| Total Operating Expenses | 13.13% | 14.03% | 8.81% | 7.16% | 8.84% |
| Operating Income | -20.32% | -19.68% | 142.76% | 139.09% | 17.44% |
| Income Before Tax | -12.88% | -12.19% | 101.17% | 98.12% | 54.96% |
| Income Tax Expenses | 15.95% | 16.87% | 80.04% | 77.32% | 77.95% |
| Earnings from Continuing Operations | -16.91% | -16.24% | 104.63% | 101.53% | 52.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.91% | -16.24% | 104.63% | 101.53% | 52.22% |
| EBIT | -20.32% | -19.68% | 142.76% | 139.09% | 17.44% |
| EBITDA | -18.40% | -17.75% | 124.13% | 120.74% | 14.95% |
| EPS Basic | -16.81% | -16.38% | 105.16% | 101.26% | 51.63% |
| Normalized Basic EPS | -13.86% | -13.25% | 104.55% | 100.88% | 43.10% |
| EPS Diluted | -8.13% | -7.21% | 103.87% | 100.63% | 36.60% |
| Normalized Diluted EPS | -11.18% | -11.18% | 104.55% | 100.88% | 38.79% |
| Average Basic Shares Outstanding | 0.14% | 0.14% | 0.03% | 0.03% | 0.19% |
| Average Diluted Shares Outstanding | -2.34% | -2.34% | 0.05% | 0.05% | 2.63% |
| Dividend Per Share | 1.12% | 2.27% | 174.47% | 170.83% | 178.13% |
| Payout Ratio | 2.44% | 2.44% | -- | -- | -0.41% |